inulbabtokceng ayeksurayekwaduk54gtreqqww

Start: Monday, April 28, 2025 12:00AM
End: Wednesday, April 30, 2025 12:00AM

Bifidobacterium-positive proximal colon cancers. Proximal colon cancer is a type of colon cancer that occurs on the right side of the colon and can have worse survival outcomes than cancers that occur in the distal colon, which is on the left side.

Ugai says the bacteria in yogurt appear to promote an overall healthy balance of bacteria in the gut. And that, in turn, promotes a strong and healthy gut barrier, which is important, because when the gut barrier becomes too permeable, it can lead to inflammation and increase the risk of colon cancer.

"My message is, if you like yogurt, go for it," Ugai says.

Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) showed higher rates of invasive-disease-free survival and overall survival as compared to trastuzumab (Herceptin) alone for patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy, as demonstrated in results from the KATHERINE trial (NCT01772472).1

“This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues,” wrote KATHERINE investigators in The New England Journal of Medicine.

Patients enrolled in the phase 3, open-label trial continued to see an improvement in invasive disease-free survival with T-DM1 vs trastuzumab at a median follow-up of 8.4 years (unstratified HR = 0.54; 95% CI, 0.44-0.66). Particularly, 19.7% of patients in the T-DM1 group and 32.2% of patients in the trastuzumab group experienced invasive disease events or death.

Seven-year invasive disease-free survival was achieved in 80.8% of patients treated with T-DM1 and 67.1% of patients on trastuzumab (difference, 13.7 percentage points).

The trial included patients with HER2-positive early breast cancer who had received neoadjuvant treatment, which included a taxane-based chemotherapy and/or trastuzumab, and had residual invasive cancer in the breast or resected axillary nodes. Patients were randomly assigned to receive either T-DM1 (n = 743) or trastuzumab (n = 743). Patients were stratified by clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status after neoadjuvant therapy.

more more more more more more more more more more more more more more more more more more more more more more more more more more more more